JACC in a Flash | Ushering in a 'New Era For JACC'; PFA Promising in Reducing AA Burden; More
Ushering in a 'New Era For JACC'
"Transitions are opportunities. They are full of possibilities, marking a juncture that combines an end and a beginning," writes Harlan M. Krumholz, MD, SM, FACC, in his first Editor's Page as editor-in-chief of JACC. "For JACC, the editorial transition is a moment to honor the past and seize the potential of the future."
Krumholz, who officially assumed the editor-in-chief role this month, outlines his strategy and vision for the journal going forward as part of his first issue. We also hear from Eugene Braunwald, MD, MACC, on the passing of the proverbial editorship torch.
Also, don't miss a State-of-the-Art Review addressing the use of artificial intelligence to transform cardiovascular care; a Cardiovascular Medicine and Society feature looking at "inflammation, colchicine and atherosclerotic disease," and whether familial Mediterranean fever is an exception that proves the rule; and much more.
Visit JACC.org for the complete lineup and look for a more in-depth interview with Krumholz next month on his plans to streamline the author process; engage in strategic partnerships, and find new and innovative ways to position JACC as the leading beacon for advancing global cardiovascular health.
Featured topics and Editors' Picks from all of ACC's JACC Journals. The results from several of the hottest trials presented at Heart Rhythm 2024 were simultaneously published in JACC Journals. Check out some of the highlights on these pages and Click here to access the complete list of simultaneous publications from this and other recent scientific meetings.
Endocardial (ENDO)-only ventricular tachycardia (VT) ablation has been found to indicate long-term VT-free survival in more than half of patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) and more than 75% if VT noninducibility is achieved following ablation, according to the results of a study presented at Heart Rhythm 2024 and simultaneously published in JACC: Clinical Electrophysiology.
Pulsed field ablation (PFA) was shown to be effective in treating patients with paroxysmal atrial fibrillation (AFib), with more patients free from atrial arrhythmias (AA) compared with patients treated with thermal ablation, according to results from a secondary analysis of the ADVENT randomized clinical trial. The results of the single-blind study were presented at Heart Rhythm 2024 and simultaneously published in JACC.
Similar clinical outcomes were observed among men and women undergoing left bundle branch area pacing (LBBAP) for CRT, and men undergoing LBBAP had a lower risk of heart failure (HF)-related hospitalizations and all-cause mortality compared with men undergoing biventricular pacing (BIVP), according to a study presented at Heart Rhythm 2024 and simultaneously published in JACC: Clinical Electrophysiology.
The baseline CHA2DS2-VASc score helped to identify patient with subclinical atrial fibrillation (SCAF) in whom the benefit for reducing the risk of stroke and systemic embolism (SE) with an oral anticoagulant (OAC) was greater than the risk of increased major bleeding, according to a subgroup analysis from the ARTESiA study presented at Heart Rhythm 2024 and simultaneously published in JACC.
Pulsed field energy ablation (PFA) was significantly associated with hemolysis compared with radiofrequency ablation (RFA) following pulmonary vein isolation (PVI), according to the results of a study presented at Heart Rhythm 2024 and simultaneously published in JACC: Clinical Electrophysiology.
Clinical Topics: Arrhythmias and Clinical EP, Cardiovascular Care Team, Heart Failure and Cardiomyopathies, Implantable Devices, EP Basic Science, SCD/Ventricular Arrhythmias, Atrial Fibrillation/Supraventricular Arrhythmias, Statins, Acute Heart Failure
Keywords: Cardiology Magazine, ACC Publications, Cardiology, Artificial Intelligence, Sex Characteristics, Heart Failure, Cardiac Resynchronization Therapy, Hospitalization, Atrial Fibrillation, Anti-Arrhythmia Agents, Autonomic Denervation, Stroke Volume, Ventricular Fibrillation, Catheter Ablation, Hemolysis, Pulmonary Veins, Radiofrequency Ablation, Haptoglobins, Prospective Studies, Bilirubin
